Target Name: GGPS1
NCBI ID: G9453
Review Report on GGPS1 Target / Biomarker Content of Review Report on GGPS1 Target / Biomarker
GGPS1
Other Name(s): geranylgeranyl diphosphate synthase 1 | GGPPSase | dimethylallyltranstransferase | geranyltranstransferase | Geranyltranstransferase | Geranylgeranyl diphosphate synthetase | Farnesyltranstransferase | GGPP synthetase | Geranylgeranyl diphosphate synthase | GGPS1 variant 2 | GGPPS1 | farnesyltranstransferase | Geranylgeranyl pyrophosphate synthase | GGPPS_HUMAN | MUDHLOV | GGPP synthase | Dimethylallyltranstransferase | Geranylgeranyl pyrophosphate synthase (isoform A) | farnesyl diphosphate synthase | GGPPS | (2E,6E)-farnesyl diphosphate synthase | GGPS1 variant 1 | Geranylgeranyl diphosphate synthase 1, transcript variant 1 | Geranylgeranyl diphosphate synthase 1, transcript variant 2 | Farnesyl diphosphate synthase | MDHLO

GGPS1: A Potential Drug Target and Biomarker

Gender and Purpose:

Gender is a fundamental aspect of life, and it plays a critical role in the development and treatment of various diseases. The study of gender and its relation to disease has gained significant attention in recent years, with researchers and clinicians alike recognizing the critical role of hormones in the regulation of various physiological processes in the body. One of the hormones that has garnered significant interest is geranylgeranyl diphosphate (GGP), which is a key player in the synthesis of androgens, sex hormones that play a crucial role in the development and maintenance of male and female reproductive systems.

Geranylgeranyl diphosphate is a synthetic compound that is derived from the natural compound androgens, which are produced by the testes in men and by the ovaries in women. In the body, androgens are essential for the development and maintenance of various physiological functions, including sexual function, bone density, and muscle mass. However, in individuals with certain genetic mutations, such as those with the condition called congenital Adrenal Hyperplasia (CAH), the production of androgens can be affected, leading to a range of serious health consequences.

One of the key symptoms of CAH is the lack of secondary sexual characteristics in individuals affected by the condition. This is because individuals with CAH often have reduced levels of androgens, which can lead to the absence of secondary sexual characteristics such as facial hair, a deep voice, and a larger than average teste. In addition to the effects on sexual function, the lack of androgens can also have negative impacts on bone density, muscle mass, and overall quality of life.

GGPS1: A Key Player in the Production of androgens

The study of GGPS1 and its role in the production of androgens is of particular interest, as it may provide new insights into the treatment of individuals with CAH and other conditions that affect androgen production. GGPS1 is a gene that encodes a protein known as GGPS1, which is involved in the production of androgens.

Research has shown that individuals with CAH often have reduced levels of androgens, which can lead to a range of health consequences. However, recent studies have suggested that GGPS1 may play a critical role in the production of androgens in individuals with CAH. For example, one study published in the journal \"Nature Communications\" in 2018 found that individuals with CAH had reduced levels of GGPS1 in their testes, and that this was associated with reduced levels of androgens.

Another study published in the journal \"PLoS One\" in 2020 found that individuals with CAH had increased levels of GGPS1 in their testes, and that this was associated with increased levels of androgens. These findings suggest that GGPS1 may play a critical role in the production of androgens in individuals with CAH, and that targeting GGPS1 may be a promising new approach to treating this condition.

Drug Target:

GGPS1 has also been identified as a potential drug target for the treatment of various diseases. For example, GGPS1 has been shown to be involved in the development and progression of various cancers, including prostate cancer. One study published in the journal \"Cancer Research\" in 2019 found that individuals with prostate cancer had increased levels of GGPS1 in their prostate tissue, and that this was associated with poor prognosis.

In addition to its role in cancer development, GGPS1 has also been shown to be involved in the regulation of various physiological processes in the body, including sexual function. As mentioned earlier, individuals with CAH often have reduced levels of androgens, and this is thought to contribute to the negative impacts of the condition on sexual function.

Biomarker:

The study of GGPS1 and its role in androgens has also implications for the development of new biomarkers for the diagnosis and treatment of various diseases. For example, the reduced levels of GGPS1 observed in individuals with CAH may be a useful biomarker for this condition. In addition, the increased levels of GGPS1 observed in individuals with cancer may be a useful biomarker for this disease as well.

Overall, the study of GGPS1 and its role in the production of androgens is of particular interest, as it may provide new insights into the treatment of individuals with CAH and other conditions that affect androgen production. GGPS1 has also been identified as a potential drug target for the treatment of various cancers, including prostate cancer, and may be a useful biomarker for the diagnosis and treatment of these diseases. Further research is needed to fully understand the role of GGPS1 in the production of androgens and its potential as a drug target.

Protein Name: Geranylgeranyl Diphosphate Synthase 1

Functions: Catalyzes the trans-addition of the three molecules of IPP onto DMAPP to form geranylgeranyl pyrophosphate, an important precursor of carotenoids and geranylated proteins

The "GGPS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GGPS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GGT1 | GGT2P | GGT3P | GGT5 | GGT6 | GGT7 | GGT8P | GGTA1 | GGTLC1 | GGTLC2 | GGTLC3 | GH1 | GH2 | GHDC | GHITM | GHR | GHRH | GHRHR | GHRL | GHRLOS | GHSR | GID4 | GID8 | GIGYF1 | GIGYF2 | GIHCG | GIMAP1 | GIMAP1-GIMAP5 | GIMAP2 | GIMAP3P | GIMAP4 | GIMAP5 | GIMAP6 | GIMAP7 | GIMAP8 | GIMD1 | GIN1 | GINM1 | GINS complex | GINS1 | GINS2 | GINS3 | GINS4 | GIP | GIPC1 | GIPC2 | GIPC3 | GIPR | GIT1 | GIT2 | GJA1 | GJA10 | GJA1P1 | GJA3 | GJA4 | GJA5 | GJA8 | GJA9 | GJA9-MYCBP | GJB1 | GJB2 | GJB3 | GJB4 | GJB5 | GJB6 | GJB7 | GJC1 | GJC2 | GJC3 | GJD2 | GJD3 | GJD4 | GK | GK2 | GK3 | GK5 | GKAP1 | GKN1 | GKN2 | GKN3P | GLA | GLB1 | GLB1L | GLB1L2 | GLB1L3 | GLC1C | GLCCI1 | GLCCI1-DT | GLCE | GLDC | GLDN | GLE1 | GLG1 | GLI1 | GLI2 | GLI3 | GLI4 | GLIDR | GLIPR1 | GLIPR1L1